Saltar a contenido principal
Saltar a Buscador
Saltar a menú servicios
Saltar a Noticias y Convocatorias - Menú principal. Secciones - - Fin de Menú principal -
- Título de la Sección Seleccionada - - Título de la Sección Seleccionada -
transferencia
- Información de interés -
foto1
foto2
- Fin de Información de interés -
- Información principal -

Home >> Transference & Innovation >> Second-round Venture Capital Investment

Loans for Second-round Venture Capital Investment

 Coming up shortly

Note: The following information is an advance on an accompanying measure for loans to venture capital investments in biotechnology companies.  It aims at anticipating the main characteristics of the new financial mechanism to potential beneficiaries (technology-based companies and venture capital companies).  Therefore, the contents of this page should not be considered binding, rather a guideline, until its final publication in the BOE (official governmental gazette).

 

Objective

To cofinance second-round investments subscribed by seed and venture capital investors for biotechnology-based companies (approved by the Spanish stock-market commission, CNMV) .

 

Action Plan

Among the technology-based companies participated by seed and venture capital investors, and particularly among biotech firms, it is usually found second (and subsequent) rounds of investments to finance business activities until the business has begun to generate revenue. The aim of this new mechanism is to co-finance by means of a non-equity loan biotech companies in the consolidation phase, which go on to a second round of investment.  However, the venture capital firm must have already shares in the biotech, which accessses this new round of funding.  To this extent, the loan has an accompanying and incentive character for the risk capital by mobilising private investments in high-risk technology companies.

The co-financing by Genoma España is set to loans up to €450,000 (€ 150,000/year over 3 years) for the company that reinvests its venture capital in the form of participatory credit without collateral, with a 10% interest rate on the total amount of the loan, after making profits, and only if it has obtained benefits.  The loan repayment will be held for upto 10 years with 3 year grace period.
 

Loan Characteristics

  • Maximum amount of credit: 450.000 €
  • Maximum percentage: 50% of the total investment
  • The total investment must be superior to 500.000 € (preferably between 1 and 3 M€)

 

Total budget set aside for this line of credit: 2.000.000 €

 

- Buscador -
- Menu de Servicios -
Services
- Últimas Noticias o Eventos -
Highlights
Notice
Pedro Teixeira, 8, planta 2 - 28020 Madrid
Request for Applications
Open Valorization Period
Request for Applications
Open Registration Period
Link
Supercomputing Centre of Castilla and Leon
Report
Challenges in Implementing more Preventive Medicine and Focused on Early Treatment
Request for Applications
Open Registration Period
Report
Comprehensive analysis of the relevance of biotechnology in Spain and its progress during the period 2000-2008
Offers
Summary and results of the 2009 Client Satisfaction Survey

© Genoma España. Actualizado Enero 2010. Aviso legal | Mapa Web
C/ Pedro Teixeira, 8 – 2ª planta. 28020 Madrid, España. Tel.: +3491 449 12 50. Fax.: +34 91 571 54 89.  info@gen-es.org

 


 

XHTML 1.0 Strict Valido   Nivel Doble-A de Conformidad   CSS válida